Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 27;94(22):e01677-20.
doi: 10.1128/JVI.01677-20. Print 2020 Oct 27.

Ionic Strength-Dependent, Reversible Pleomorphism of Recombinant Newcastle Disease Virus

Affiliations

Ionic Strength-Dependent, Reversible Pleomorphism of Recombinant Newcastle Disease Virus

Benjamin S Rush et al. J Virol. .

Abstract

A genetically modified, recombinant form of Newcastle disease virus (rNDV) undergoes ionic strength-dependent changes in morphology, as observed by cryo-electron microscopy (cEM). In hypotonic solutions with ionic strengths ranging from < 0.01 to 0.02 M, rNDV virions are spherical or predominantly spherical. In isotonic and hypertonic solutions, rNDV displays pleomorphism and contains a mixed population of spherical and elongated particles, indicating that a change from spherical to elongated shape is induced with increasing salt concentration. This ionic strength-dependent transition is largely reversible, as determined by cEM. Concomitantly, we measured infectious titers of these same rNDV samples at different ionic strengths using a fluorescent focus assay (FFA). The infectivity of oncolytic rNDV was found to be independent of ionic strength, ranging from 0.01 M to approximately 0.5 M. These structural and functional observations, in combination, suggest that infectivity (and, by inference, oncolytic activity) of rNDV virions is fully maintained in their pleomorphic forms.IMPORTANCE Oncolytic viruses are being developed for cancer therapy, as they selectively target, infect, and kill cancer cells. NDV is particularly attractive because while it is pathogenic to avians (e.g., chickens), it does not cause significant viremia in humans. We have developed a genetically modified recombinant NDV (rNDV) that has much reduced pathogenicity in chickens but is highly oncolytic. The morphology of rNDV transitions from spherical at very low salt concentrations to a heterogeneous population of spherical and elongated virions in isotonic (physiologic salt concentration) and hypertonic solutions. The infectivity (cell-killing activity by infecting cells) of rNDV is unaltered by changes in salt concentration despite morphological changes. These observations are significant for purification and formulation of rNDV, as exposure to different salt concentrations may be needed. Importantly, at physiological salt concentration, relevant to clinical testing, infectivity and, therefore, oncolytic activity will not be compromised despite morphological heterogeneity.

Keywords: Newcastle disease virus; cryo-electron microscopy; fluorescent focus assay; genetically modified; infectious titer; ionic strength; oncolytic activity; pleomorphism; recombinant; recombinant Newcastle disease virus; reversible; virion morphology.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Cryo-EM images (×52,000 magnification) of rNDV samples incubated in different salt concentrations and ionic strengths (μ) while maintaining the pH at 7.0. (A) 6.5 mM sodium phosphate, 150 mM NaCl, μ = 0.160 M; (B) 5.3 mM sodium phosphate, 3.0 mM NaCl, 0.2% sucrose, μ = 0.011 M; (C) after incubation at μ = 0.011 M. As in panel B, the rNDV sample was incubated in 5.8 mM sodium phosphate, 258 mM NaCl, 0.06% sucrose, μ = 0.275 M. The purpose was to test if the ionic strength-dependent change in morphology was reversible between spherical and elongated shapes.

References

    1. Alexander DJ. 2000. Newcastle disease and other avian paramyxoviruses. Rev Sci Tech 19:443–462. doi:10.20506/rst.19.2.1231. - DOI - PubMed
    1. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson ES, Irving CS, Galun E, Siegal T. 2006. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13:221–228. doi:10.1016/j.ymthe.2005.08.016. - DOI - PubMed
    1. Yaacov B, Eliahoo E, Elihaoo E, Lazar I, Ben-Shlomo M, Greenbaum I, Panet A, Zakay-Rones Z. 2008. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther 15:795–807. doi:10.1038/cgt.2008.31. - DOI - PubMed
    1. Cheng X, Wang W, Xu Q, Harper J, Carroll D, Galinski MS, Suzich J, Jin H. 2016. Genetic modification of oncolytic Newcastle disease virus for cancer therapy. J Virol 90:5343–5352. doi:10.1128/JVI.00136-16. - DOI - PMC - PubMed
    1. Rangaswamy US, Cotter CR, Cheng X, Jin H, Chen Z. 2016. CD55 is a key complement regulatory protein that counteracts complement mediated inactivation of Newcastle disease virus. J Gen Virol 97:1765–1770. doi:10.1099/jgv.0.000498. - DOI - PubMed